all report title image

MICROSCLEROTHERAPY TREATMENT MARKET ANALYSIS

Microsclerotherapy Treatment Market, By Product Type (Sclerosant (Detergent-based (Sodium Tetradecyl Sulphate and Ethanolamine Oleate)), Chemical-Based (Chromated Glycerin), Osmotic Agents (Hypertonic Saline or Hypertonic Glucose), Needles, (Others), By End Users (Hospitals, Aesthetic Treatment Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI3372
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Microsclerotherapy Treatment MarketSize and Trends

Microsclerotherapy Treatment Market Drivers-

Leading manufacturers are indulged in the development and commercialization of new sclerosants which would be used in the treatment of varicose veins such as hypertonic saline, sodium tetradecyl sulphate, and polidocanol. For instance, Medtronic Plc launched a new product, Venaceal closure system in U.S., in November 2015. The new product is non-invasive and uses a proprietary medical adhesive instead of a sclerosant to seal the varicose veins and is effective for patients suffering from varicose veins by eliminating the need for anesthesia, several injections, and use of compression stockings post operation, thus reducing the disadvantages caused by using sclerosants.

Moreover, in 2014, BTG international Inc. launched varithena (polidocanol) which decreases the symptoms, appearance of varicose veins as well as achiness, itching, and swelling of the veins. Furthermore, manufacturers are also focused on inorganic growth strategies such as mergers and acquisitions. For instance, in August 2019, Boston Scientific acquired BTG International, Inc as BTG manufactures and commercialize products used in minimally invasive treatments used for targeting cancer and other vascular diseases.

According the National Center for Biotechnology Information (NCBI), 2019, 41% people in the U.S. suffer from varicose veins and around 41% of women population and 50% of the men population all over the world, over the age of 50 have telangiectasia. According to NCBI, 2018, lower limb varicose veins are very common and over 10 – 30% of the world wide population suffers from telangiectasia. During the onset of periods and pregnancy, most of the women are prone to telangiectasia. Other reasons are standing and sitting for long periods of time, sitting cross legged, obesity, and others. High incidence of telangiectasia is expected to boost the global microsclerotherapy treatment market growth in the near future.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.